A detailed history of Prelude Capital Management, LLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Prelude Capital Management, LLC holds 36,900 shares of CNTA stock, worth $646,857. This represents 0.04% of its overall portfolio holdings.

Number of Shares
36,900
Previous 36,900 -0.0%
Holding current value
$646,857
Previous $590,000 -0.0%
% of portfolio
0.04%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.58 - $16.99 $274,560 - $543,680
-32,000 Reduced 46.44%
36,900 $590,000
Q2 2024

Aug 14, 2024

SELL
$8.04 - $11.87 $1,680 - $2,480
-209 Reduced 0.3%
68,900 $622,000
Q1 2024

May 15, 2024

BUY
$6.73 - $12.2 $465,103 - $843,129
69,109 New
69,109 $780,000
Q2 2022

Aug 15, 2022

SELL
$3.18 - $9.85 $36,252 - $112,290
-11,400 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$7.45 - $11.59 $84,930 - $132,126
11,400 New
11,400 $102,000

Others Institutions Holding CNTA

About Centessa Pharmaceuticals plc


  • Ticker CNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,339,296
  • Market Cap $1.65B
  • Description
  • Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...
More about CNTA
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.